We are grateful to all the researchers and scientists worldwide who have used our products. It is extremely rewarding for us to know that our products work for you. The following are some publications in which Selleck products have been used.
Vila Gasull, et al. Polysaccharide-gold nanoparticles as anticancer drugs carriers. Faculty of Engineering of the University of Porto, 2011, .
Fernández-Acero T, et al. A Yeast-Based In Vivo Bioassay to Screen for Class I Phosphatidylinositol 3-Kinase Specific Inhibitors. J Biomol Screen, 2012, 17(8):1018-29.
Kosztyu P, et al. Can P-glycoprotein mediate resistance to nilotinib in human leukemia cells? Pharmacol Res, 2013, 67(1):79-83.
Jia L, et al. Defining pathways of spindle checkpoint silencing: functional redundancy between Cdc20 ubiquitination and p31comet. Mol Biol Cell, 2011, 22(22):4227-35.
Akimov V, et al. Characterization of ubiquitination dependent dynamics in growth factor receptor signaling by quantitative proteomics Mol Biosyst, 2011, 7(12):3223-33.
Sen N, et al. Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A, 2012, 109(2):600-5.
Hingorani P, et al. BIRC5 expression is a poor prognostic marker in Ewing sarcoma. Pediatr Blood Cancer, 2013, 60(1):35-40.
Kumar B, et al. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther, 2012, 11(9):1988-98.
Yoon DH, et al. The Survivin Suppressant YM155 Potentiates Chemosensitivity to Gemcitabine in the Human Pancreatic Cancer Cell Line MiaPaCa-2. Anticancer Res, 2012, 32(5):1681-8.
